Wall Street analysts expect that Omnicell, Inc. (NASDAQ:OMCL) will announce earnings of $0.67 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Omnicell’s earnings. The lowest EPS estimate is $0.66 and the highest is $0.68. Omnicell posted earnings per share of $0.54 during the same quarter last year, which would indicate a positive year over year growth rate of 24.1%. The business is scheduled to report its next earnings results on Thursday, February 7th.

According to Zacks, analysts expect that Omnicell will report full-year earnings of $2.04 per share for the current financial year, with EPS estimates ranging from $2.03 to $2.06. For the next financial year, analysts expect that the firm will post earnings of $2.40 per share, with EPS estimates ranging from $2.35 to $2.45. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Omnicell.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The company had revenue of $204.27 million for the quarter, compared to analyst estimates of $203.48 million.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, September 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $80.00 price objective (up from $70.00) on shares of Omnicell in a report on Thursday, December 6th. Craig Hallum increased their price objective on shares of Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a report on Monday, September 17th. Zacks Investment Research reiterated a “strong-buy” rating and issued a $78.00 price objective on shares of Omnicell in a report on Wednesday, November 14th. Finally, Oppenheimer increased their price objective on shares of Omnicell to $86.00 and gave the company an “outperform” rating in a report on Friday, December 7th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $73.75.

Omnicell stock opened at $65.28 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.78 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $2.56 billion, a PE ratio of 362.67, a P/E/G ratio of 2.99 and a beta of 1.20. Omnicell has a 12-month low of $39.75 and a 12-month high of $79.48.

In related news, EVP Dan S. Johnston sold 6,250 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $63.47, for a total transaction of $396,687.50. Following the completion of the sale, the executive vice president now directly owns 35,996 shares in the company, valued at $2,284,666.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Peter J. Kuipers sold 5,574 shares of the firm’s stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $70.11, for a total transaction of $390,793.14. Following the sale, the insider now owns 51,542 shares of the company’s stock, valued at $3,613,609.62. The disclosure for this sale can be found here. Insiders have sold 30,160 shares of company stock valued at $1,973,926 over the last 90 days. 3.71% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Stone Ridge Asset Management LLC purchased a new stake in shares of Omnicell in the 3rd quarter valued at approximately $202,000. Everence Capital Management Inc. purchased a new stake in shares of Omnicell in the 3rd quarter valued at approximately $204,000. Ibex Investors LLC purchased a new stake in shares of Omnicell in the 3rd quarter valued at approximately $209,000. Evanston Investments Inc. dba Evanston Advisors purchased a new stake in shares of Omnicell in the 3rd quarter valued at approximately $216,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Omnicell in the 3rd quarter valued at approximately $237,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: How the Consumer Price Index (CPI) is calculated?

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.